Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. |
| |
Authors: | Murat T?rüner Ozlem Erkan Irfan Soykan Mithat Bozdayi Hülya Cetinkaya Cihan Yurdaydin Ozden Uzunalimo?lu Ali Ozden |
| |
Affiliation: | Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey. |
| |
Abstract: | BACKGROUND/AIMS: Thromboembolic events are more common in patients with inflammatory bowel disease than in the normal population; however, the reason for the increased prevalence is not clear. The aim of this study was to evaluate the prevalence of factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase (MTHFR) gene mutations in IBD patients followed in our outpatient clinic. METHODS: Thirty-four patients with ulcerative colitis and 28 patients with Crohn's disease and 80 healthy controls were included in the study. No patient had a history of previous thromboembolism. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations were studied. RESULTS: Heterozygote factor V Leiden mutation was found in five (6.25%) control patients and in two (3.2%) IBD patients. Heterozygote MTHFR mutation was obtained in seven (11.3%) IBD patients and in five (6.25%) controls. Heterozygote prothrombin G20210A mutation was found in two (2.5%) and homozygote MTHFR mutation in one (1.25%) control patient. There was no statistical difference between the IBD group and healthy controls. CONCLUSIONS: Genetic mutations that could increase the thrombosis risk were not found to be different in IBD versus the normal population in our study. |
| |
Keywords: | |
|
|